



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 14 Feb 2022 (#6)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

## Important Notices

- **Financial Conflict of Interest:** The NIH is committed to preserving the public's trust that the research we supports is conducted without bias and with the highest scientific and ethical standards. The regulation on promoting objectivity in research establishes the standards to provide a reasonable expectation that the design, conduct, and reporting of NIH research will be free from bias resulting from investigators' financial conflicts of interest. NIH requires recipient [institutions](#) and investigators to comply with the requirements of [42 CFR 50, Subpart F, Promoting Objectivity in Research](#) (FCOI Regulation), as implemented in [Final Rule](#) for grants and cooperative agreements.

**Principal Investigators (PIs) and Key Personnel (KP) of all current NIH grants, direct and subawards, must complete the NIH training and submit the certificate the Grants Management Office) not later than 31 March 2022.** For all new applications, all PI's & KP must complete the certificate before the application can be submitted to NIH. This is in addition to the FCOI declarations that must be signed.

- FHMS contact: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za)
- Stellenbosch Campus contact [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za).

**Link to the training:** [https://grants.nih.gov/grants/policy/coi/tutorial2018/story\\_html5.html](https://grants.nih.gov/grants/policy/coi/tutorial2018/story_html5.html)

Training on the Stellenbosch University policy on FCOI, which is also a requirement of **42 CFR 50**, will be offered soon and will be communicated through this newsletter and other communication channels.

- **NOT-OD-22-018 Reminder: FORMS-G Grant Application Forms & Instructions Must be Used for Due Dates On or After January 25, 2022 - New Grant Application Instructions Now Available.** This Notice reminds the applicant and recipient community that applicants must use FORMS-G application packages for due dates on or after January 25, 2022 and must use FORMS-F application packages for due dates on or before January 24, 2022 (see [NOT-OD-21-169](#) for details). FORMS-G Grant Application Instructions are now posted on the [How to Apply - Application Guide](#) page.
- **NOT-OD-21-110 Implementation of Changes to the Biographical Sketch and Other Support Format Page.** This notice describes implementation of the updated Other Support and Biosketch format pages and associated instructions, as outlined in [NOT-OD-21-073](#). NIH will require the use of the updated format pages. Failure to follow the appropriate formats on or after January 25, 2022 may cause NIH to withdraw applications from funding. Use of ScienCV Biosketch <https://www.ncbi.nlm.nih.gov/sciencv/> is strongly recommended. NIH is fully committed to implementing the SciENcv template for Other Support in early FY 2022. Examples are available from [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za).
- **In December, NIH published a revised [Grants Policy Statement \(GPS\)](#) for fiscal year 2022.** The NIH GPS provides policy instruction that serves as the standard terms and conditions of award for NIH grants, as well

as guidance for applicants pursuing an NIH grant. Refer to [Summary of Significant Changes to the NIH GPS for December 2021 Version](#)

- [NOT-AI-22-033](#) **Notice of Availability of Frequently Asked Questions related to [PAR-20-108](#), "International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)"** This Notice informs interested parties of the availability of Frequently Asked Questions (FAQs) related to the FOA. Application due date is 15 July 2022. The FAQs for this FOA can be found at: <https://www.niaid.nih.gov/grants-contracts/questions-answers-par-20-108>.
- [NOT-NS-22-060](#) **Notice of Correction to [PAR-21-237](#) "NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)"**. This notice is to inform applicants of a correction to [PAR-21-237](#). This notice has been corrected to show that the initial milestone driven planning phase (UG3) will last for **one year**, with possible transition to the clinical phase, as outlined in the FOA.

## Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Notices of Special Interest

- [NOT-MH-22-085](#): **Notice of Special Interest (NOSI): Administrative Supplements for NIMH Grants to Inform the Assessment of Suicide Thoughts and Behaviors among Children and Preteens.** The purpose of this Notice of Special Interest (NOSI) is to encourage research focused on informing or refining developmentally and culturally sensitive approaches for assessing suicide thoughts and behaviors (STB) among children and preteens (defined here as 12-years-old and younger). Supplement applications are encouraged from currently funded projects with infrastructure that can be readily leveraged to inform the development or refinement of developmentally and culturally sensitive approaches for assessing suicide thoughts and behaviors (STB) among children and preteens. Examples of projects that might be candidates for supplement activities include:
  - Studies that are focused on risk for, etiology/course of, or interventions for psychopathology among children/preteens
  - Projects that focus on the assessment and phenomenology of suicidal thoughts and behavior among adolescent-aged youth, where investigator expertise and assessment protocols could be leveraged and extended to develop and refine developmentally appropriate approaches for assessment with younger children

NIMH will accept and review administrative supplement applications in response to this announcement on a continuous basis until **1 April 2022**, by 5:00 PM local time of the applicant organization. Applications for this initiative must be submitted using the following opportunity [PA-20-272](#) - Administrative Supplements to Existing NIH Grants and Cooperative Agreements.

- [NOT-MH-22-086](#) **Notice of Special Interest (NOSI): Assessment of Suicide Thoughts and Behaviors among Children and Preteens.** The purpose of this Notice of Special Interest (NOSI) is to encourage advance research that addresses outstanding questions related to the developmentally and culturally appropriate characterization

and assessment of STB in children/preteens. For purposes of this NOSI, children/preteens are defined as youth 12 years old and younger. NIMH encourages applications that consider issues relevant to the assessment of diverse youth, including the acceptability and cultural relevance of the strategies for assessment among youth from minoritized backgrounds and/or sexual and gender minority youth. Submit applications for this initiative using one of the following FOA [PA-21-235](#) - NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed). Due Dates: 16 June 2022 to 8 May 2024.

- **[NOT-MH-22-110](#) Notice of Special Interest (NOSI): Priority Research Opportunities in Crisis Response Services.** National Institutes of Health seeks research conducted in real-world settings, where a wide range of clinical presentations, psychosocial factors, age-related (e.g., youth; adult; older adult), geographic (rural/remote settings), cultural considerations, and health disparities influence the types of care that are provided. Examples of NIMH and NIDA studies that are encouraged through this Notice address the continuum of crisis service systems. Applications that include crisis services for children and under-resourced populations are encouraged. Topics of research interest span the crisis care continuum, including the effectiveness of these components: call center capabilities to address distress and coordinate care, deployed mobile crisis outreach and support, and crisis services that can diagnose and provide short term stabilization. Applicants must select the IC and associated FOA to use for submission of an application in response to the NOSI. The selection must align with the IC requirements listed in order to be considered responsive to that FOA. Non-responsive applications will be withdrawn from consideration for this initiative. This notice applies to due dates on or after 5 June 2022 and subsequent receipt dates through 8 May 2025.
- **[NOT-OD-22-068](#) Notice of Special Interest (NOSI): Administrative Supplements to Support Enhancement of Software Tools for Open Science.** This Notice announces the continuing availability of administrative supplements to active awards that focus on biomedical software development or have a significant software development component. The goal of these supplements is to invest in research software tools with recognized value in a scientific community to enhance their impact by leveraging best practices and design principles in software development and advances in technology including cloud computing. This initiative is part of a plan for implementing the [NIH Strategic Plan for Data Science](#) which describes actions aimed at modernizing the biomedical research data ecosystem to make data findable, accessible, interoperable, and reusable (FAIR) and provide robust, scalable, sustainable tools and workflows with high impact for open science. The supplements are intended to support and encourage collaborations between biomedical scientists and software engineers to enhance the design, implementation, and cloud-readiness of research software. Through these awards, the NIH Office of Data Science Strategy ([ODSS](#)) intends to help researchers who have developed scientifically valuable software to make their tools robust and sustainable, take advantage of new data science, software engineering, and computing paradigms, reach a broader community and contribute to open science. To be eligible, the parent award must be able to receive funds in FY2022 (1 Oct 2021 – 30 Sept 2022) and not be in the final year or in a no-cost extension period as of 1 July 2022. Projects that have already received awards under [NOT-OD-20-073](#) or [NOT-OD-21-091](#) are NOT eligible for this NOSI. One-time supplement budget requests cannot exceed \$150,000 direct costs. The number of awards will be contingent on availability of funds and receipt of meritorious applications. It is currently anticipated that 20 awards or more will be made depending on available funds. Application due date is **12 April 2022** by 5:00 PM local time of applicant organization.

## Funding Opportunity Announcements (FOA)

### 1. Global Brain and Nervous System Disorders Research Across the Lifespan (R01 Clinical Trials Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-22-097](#)

**Type:** R01

**Application Due Date:** Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) encourages grant applications for the conduct of innovative, collaborative research projects with low- and middle-income country (LMIC) institutions/ scientists on brain and other nervous system function and disorders throughout life, relevant to LMICs. Research on neuro-health and neurological, neuromuscular, sensory, neuropsychiatric, cognitive, behavioral and neurodevelopmental function and disorders may span the full range of science from basic to clinical to translation and implementation research. Scientists in the United States (U.S.) or upper middle-income countries (UMICs) are eligible to partner with LMIC institutions. Scientists in UMICs may partner directly with scientists at other LMIC institutions with or without a US partner. Income categories are defined by the World Bank at <http://data.worldbank.org/about/country-classifications/country-and-lending-groups>. The collaborative research programs are expected to contribute to the long-term goals of building and strengthening sustainable neuro-health research capacity in LMICs to address brain, nervous system and neuromuscular development, function and impairment throughout life

and to lead to diagnostics, treatments, prevention and implementation strategies. The proposed work will also contribute to developing a base for research networking and evidence-based policy beyond the specific research project. R01 Applications must be relevant to the mission of one of the participating ICs other than FIC. Applicants for this R01 should consult with the listed IC staff contact(s). Confirmation of interest from at least one NIH IC, other than FIC is strongly encouraged, before applying.

**Companion Funding:** [PAR-22-098](#), [R21](#) Exploratory/Developmental Grants

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. Applicants may request a project period of up to five years

## 2. Biomarker Signatures of TB Infection in Young Children With and Without HIV (R01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AI-22-015](#)

**Type:** R01

**Application Due Date:** 8 June 2022. Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to advance research to discover and validate novel biomarkers of Tuberculosis (TB) infection and subsequent risk of progression to TB disease in young children with and without HIV.

**Budget:** Issuing IC and partner component intend to commit an estimated total of \$ 2,250,000 to fund 2-3 awards. Application budgets are limited to \$700,000 in direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

## 3. Investigating Transposable Elements and Mobile DNA as Targets of Integration for Establishing HIV Reservoirs in the Brain (R61/R33 - Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-DA-23-003](#)

**Type:** R61/R33

**Application Due Date:** 3 August 2022 Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** The purpose of this funding opportunity announcement (FOA) is to support research examining the potential contributions of mobile DNA elements and addictive substances in HIV integration, reservoir formation, and maintenance in the brain. NIDA is specifically interested in studies exploring the contributions of molecular, genetic, and epigenetic factors in HIV integration, reservoir formation, and maintenance in microglia and/or the brain in **the context of addiction**.

**Budget:** National Institute on Drug Abuse ([NIDA](#)) intends to commit \$2,000,000 in FY 2023 to fund 2-3 awards. Application budgets are limited to direct costs of \$450k/year for each year of the R61 phase and \$650k/year for each year of the R33 phase, and should reflect the actual needs of the proposed project. Application budgets are limited in time to a maximum of three years for the R61 phase and two years for the R33 phase.

## 4. Integrating Mental Health Care into Health Care Systems in Low- and Middle-Income Countries (R01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-MH-22-130](#)

**Type:** R01

**Application Due Date:** 22 June 2022. **AIDS Date:** 4 August 2022. Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) invites implementation research applications to develop, optimize, and test innovative theory-based strategies to integrate mental and physical health care within health care systems in low-and middle-income countries (LMICs). This FOA aims to support innovative research for implementing, scaling up, and financially sustaining integrated mental health care models to ultimately increase demand and utilization, quality, access, and availability of mental health care. This FOA is also expected to contribute to the long-term goals of strengthening the sustainable research capacity in LMICs and enhancing the potential for multidirectional knowledge and the exchange of research advancements. NIMH encourages partnerships between institutions in LMICs and high-income-countries (HICs).

**Budget:** NIMH and NCI intend to commit \$3M in FY 2023 to fund 6-7 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

## 5. BRAIN Initiative: Targeted BRAIN Circuits Projects- TargetedBCP (R01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-NS-22-026](#)

**Type:** R01

**Application Due Date:** 1 July 2022 to 2 October 2024. Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** Reissue of [RFA-NS-21-013](#). This FOA solicits applications for research projects that seek to understand how circuit activity gives rise to mental experience and behavior using innovative, methodologically-integrated approaches. The goal is to support adventurous projects that can realize a potentially transformative outcome within 5 years. Applications are expected to address circuit function in the context of specific behaviors or neural systems, such as sensation, perception, attention, reasoning, intention, decision-making, emotion, navigation, communication, or homeostasis. Projects should link theory, data analysis, and/or computational approaches to experimental design and should produce predictive models (conceptual or quantitative). Projects should aim to improve the understanding of circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating dynamic patterns of neural activity. Diverse species or experimental systems and a cross-species/comparative approach are welcome and should be chosen based on their power to address the specific question at hand and to reveal generalizable and fundamental neuroscience principles.

**Companion Funding:** [RFA-NS-22-027](#), [R34](#) Planning Grant

**Budget:** BRAIN Initiative intends to commit up to an estimated total of \$15 M per year to fund 20 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

#### 6. BRAIN Initiative: Targeted BRAIN Circuits Planning Projects – TargetedBCPP (R34 Clinical Trials Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-NS-22-027](#)

**Type:** R34

**Application Due Date:** Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** This R34 FOA solicits applications that offer a limited scope of aims and an approach that will establish feasibility, validity, or other technically qualifying results that, if successful, would support, enable, and/or lay the groundwork for a potential, subsequent Targeted BRAIN Circuits Projects - TargetedBCP R01, as described in the companion FOA ([RFA-NS-22-026](#)). Applications should be adventurous, exploratory research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior.

**Budget:** BRAIN Initiative intends to commit up to \$2.5M per year to fund 10 awards. The combined budget for direct costs for the two-year project period may not exceed \$450,000. No more than \$225,000 may be requested in any single year. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

#### 7. HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-NS-22-050](#)

**Type:** UG3/UH3

**Application Due Date:** 11 March 2022; 23 June 2022; 13 October 2022; 23 February 2023. Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery of candidate biomarkers or biomarker signatures for pain that can be used to facilitate the testing of non-opioid pain therapeutics in Phase II clinical trials. The biomarkers or biomarker signature will be developed through clinical research specifically focused on the identification of pain biomarkers or biosignatures that *predict and/or monitor response to pain therapeutics*. The resulting biomarkers or biomarker signatures may be focused on a single pain condition or on several pain conditions with common underlying pathophysiology. Applications to identify biomarkers or biomarker signatures that predict or monitor a therapeutic response *across several related pain conditions* should feature Multiple Principal Investigator (MPI)-led teams that represent each of the related pain conditions and associated clinical networks. The MPI-led teams are expected to decide upon a single set of measures or biomarker modalities including, but not limited to a combination of omics, Quantitative Sensory Testing (QST), actigraphy, Electroencephalography (EEG), digital measures, etc. as components of the biosignature for all pain conditions represented in the application. Applications should feature centralized resource groups that will coordinate clinical trials and standardize all sample or data collection methods, technology development, statistical analysis and algorithm development across the pain conditions under investigation. Applications seeking to develop biomarkers or biomarker signatures that will be used to predict and/or monitor a therapeutic response for a *single* pain condition may also feature MPI-led teams that represent the cross functional expertise necessary for biomarker and/or signature development, along with the same types of centralized resource groups that coordinate clinical trials and standardize sample or data collection methods, technology development and statistical analysis. Studies to be supported by this FOA may include those necessary for the identification and initial biological, analytical, and clinical validation of pain biomarkers or biomarker signatures, and must include human samples and data as the source for candidate biomarkers or signatures identification and development if possible. If not, biomarkers or signatures resulting from identification in animal models must be verified in human samples at the end of the UG3 phase or during the UH3 phase. This initiative aims to deliver therapeutic response prediction and/or monitoring candidate pain biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation appropriate for use in clinical trial design or decision-making in clinical practice.

**Budget:** Issuing IC and partner components intend to issue 2-3 awards in 2022, 5-6 awards in 2023 and 3-4 awards in 2024. Awards issued under this FOA are part of funds set aside to support the HEAL (Helping to End Addiction Long-term) initiative. Application budgets are limited to <\$500,000 in direct costs per year for the UG3 phase and up to \$1,500,000 in direct costs per year of the UH3 phase. Applicants may seek two years of UG3 funding. The UH3 phase cannot exceed three years, since the total period of the UG3/UH3 award cannot be more than 5 years. The actual duration of individual projects will depend on successful achievement of milestones and conditions as described in Milestones Section of the program overview.

Research Development and Support Division (RDSD),  
Faculty of Medicine and Health Sciences, Stellenbosch University  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: [Christa](#)  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)  
Stellenbosch University  
2038 Wilcocks Building, Ryneveld Street  
Enquiries: [Lizél](#)  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105